Through the 90-day period concluding February 19, 2026, Xilio Therapeutics's top three insider stakeholders include TenPercentOwner Sciences, Inc. Gilead (9.11Mn shares), TenPercentOwner Impact Medicine Fund Lp Sv7 (3.23Mn shares), TenPercentOwner Capital Life Sciences Investors, Llc Bain (2.81Mn shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Sciences, Inc. Gilead | 9,105,451 | 19 Dec, 2024 | |
| Impact Medicine Fund Lp Sv7 | 3,227,264 | 03 Nov, 2021 | |
| Capital Life Sciences Investors, Llc Bain | 2,805,413 | 10 Dec, 2021 | |
| Venture Fund Xi, L.P. Atlas | 2,754,109 | 09 Feb, 2024 | |
| Pharmaceutical Co Ltd Takeda | 1,475,121 | 26 Oct, 2021 | |
| Venture Fund Iv, L.P. Rivervest | 1,441,444 | 26 Oct, 2021 | |
| Springs Capital Management Lp Rock | 1,256,472 | 26 Oct, 2021 | |
| James E Flynn | 1,143,972 | 28 Oct, 2021 | |
| City Capital Llc Bay | 1,129,490 | 26 Oct, 2021 | |
| Kgaa Merck | 680,825 | 26 Oct, 2021 | |
| Llc Fmr | 372,215 | 28 Oct, 2021 | |
| Rene Russo | President And Ceo | 325,422 | 05 Jan, 2026 |
| Ltd Fil | 218,705 | 28 Oct, 2021 | |
| Venture Investments, Llc Alexandria | 166,423 | 26 Oct, 2021 | |
| James Samuel Shannon | 70,000 | 18 Jun, 2025 | |
| Katarina Luptakova | Chief Medical Officer | 33,250 | 05 Jan, 2026 |
| Christopher James Frankenfield | Chief Financial Officer | 24,766 | 05 Jan, 2026 |
| Kevin M. Brennan | Svp And Finance And Accounting | 6,371 | 05 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Jan, 2026 | Kevin M. Brennan | Common Stock | D | 1,826 | $0.64 | 6,371 | D | S |
| 02 Jan, 2026 | Christopher James Frankenfield | Common Stock | D | 7,030 | $0.64 | 24,766 | D | S |
| 01 Jan, 2026 | Rene Russo | Common Stock | A | 44,250 | - | 325,422 | D | M |
| 01 Jan, 2026 | Kevin M. Brennan | Common Stock | A | 5,000 | - | 8,197 | D | M |
| 01 Jan, 2026 | Christopher James Frankenfield | Common Stock | A | 19,375 | - | 31,796 | D | M |
| 01 Jan, 2026 | Katarina Luptakova | Common Stock | A | 16,625 | - | 33,250 | D | M |
| 17 Jun, 2025 | James Samuel Shannon | - | - | 70,000 | D | |||
| 17 Jun, 2025 | James Samuel Shannon | Common Stock | A | 25,000 | $0.69 | 70,000 | D | P |
| 16 Jun, 2025 | James Samuel Shannon | Common Stock | A | 45,000 | $0.69 | 45,000 | D | P |
| 16 Jun, 2025 | James Samuel Shannon | - | - | 45,000 | D | |||
| 16 Jun, 2025 | Rene Russo | Common Stock | A | 36,289 | $0.68 | 281,172 | D | P |
| 02 Jan, 2025 | Kevin M. Brennan | Common stock | D | 1,803 | $0.98 | 3,197 | D | S |
| 02 Jan, 2025 | Kevin M. Brennan | - | - | 3,197 | D | |||
| 02 Jan, 2025 | Christopher James Frankenfield | Common stock | D | 6,954 | $0.98 | 12,421 | D | S |
| 01 Jan, 2025 | Rene Russo | Common Stock | A | 44,250 | - | 244,883 | D | M |
| 01 Jan, 2025 | Kevin M. Brennan | Common Stock | A | 5,000 | - | 5,000 | D | M |
| 01 Jan, 2025 | Christopher James Frankenfield | Common Stock | A | 19,375 | - | 19,375 | D | M |
| 01 Jan, 2025 | Katarina Luptakova | - | - | 16,625 | D | |||
| 01 Jan, 2025 | Katarina Luptakova | Common Stock | A | 16,625 | - | 16,625 | D | M |
| 18 Dec, 2024 | Sciences, Inc. Gilead | - | - | 9,105,451 | D |